Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

Witte, T. de; Hagemeijer, A.; Suciu, S.; Belhabri, A.; Delforge, M.; Kobbe, G.; ... ; Willemze, R. (2010)

Article / Letter to editor

• myelodysplastic syndromes
• secondary acute myeloid leukemia
• cytogenetic characteristics
• allogeneic stem cell transplantation
• autologous stem cell transplantation
• intensive chemotherapy

• All authors: Witte, T. de; Hagemeijer, A.; Suciu, S.; Belhabri, A.; Delforge, M.; Kobbe, G.; Selleslag, D.; Schouten, H.C.; Ferrant, A.; Biersack, H.; Amadori, S.; Muus, P.; Jansen, J.H.; Hellstrom-Lindberg, E.; Kovacsovics, T.; Wijermans, P.; Ossenkoppele, G.; Gratwohl, A.; Marie, J.P.; Willemze, R.
• Date: 2010-10-31
• Journal: Haematologica
• Volume: 95
• Issue: 10
• Pages: 1754 - 1761
• DOI: doi:10.3324/haematol.2009.019182